Michael A. Metzger, Chief Executive Officer at Syndax Pharmaceuticals Inc (SNDX), sold 314,614 shares at $16.41 ($5.2M) on 2025-09-08, disclosed to the SEC on 2025-09-08.
Scheduled sale ($5.2M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.41 | 157,307 | $2.6M | 50.0% |
| 2 | $16.41 | 157,307 | $2.6M | 50.0% |
| Total | $16.41 avg | 314,614 | $5.2M | 100% |
| Filing → |
| SNDX | SELL | 2026-02-10 | $361K | — | Filing → |
| SNDX | SELL | 2026-02-06 | $153K | — | Filing → |
| SNDX | SELL | 2025-07-18 | $140K | — | Filing → |